**Multicomponent Reactions**

General and Efficient Copper-Catalyzed Three-Component Coupling Reaction towards Imidazoheterocycles: One-Pot Synthesis of Alpidem and Zolpidem**

*Natalia Chernyak and Vladimir Gevorgyan*

Imidazopyridine is an important pharmacophore, and is widely found in many biologically active compounds.[1] In particular, imidazo[1,2-a]pyridine is an essential fragment present in pharmacologically important molecules, which include several anxyolytic drugs,[2] such as alpidem (**A**),[2a,b] necopidem (**C**), saripidem (**D**), and the drug used to treat insomnia zolpidem (**B**)[2c,d] (Scheme 1). Although a variety of

Scheme 1. Imidazo[1,2-a]pyridine-based drugs.

synthetic methods for the synthesis of these important frameworks has been developed,[3] most of them are limited in scope and require multistep preparation of the starting materials.[4] Accordingly, development of straightforward and general methods for the synthesis of imidazo[1,2-a]pyridines from easily available precursors is highly warranted. Herein, a general and efficient synthesis of imidazopyridines **5** by the copper-catalyzed three-component coupling (TCC) reaction of 2-aminopyridines **1** with aryl aldehydes **2** and alkynes **3** is reported (Scheme 2).

We reasoned that the imidazo[1,2-a]pyridyl core **5** could be assembled by a π-philic metal-catalyzed 5-exo-dig cyclization[5] of propargylamine **4** (Scheme 2). The latter, in turn, should be accessible through a three-component coupling

[*] N. Chernyak, Prof. V. Gevorgyan
Department of Chemistry, University of Illinois at Chicago
845 West Taylor Street, Room 4500, Chicago, IL 60607 (USA)
Fax: (+1) 312-355-0836
E-mail: vlad@uic.edu
Homepage: http://www.chem.uic.edu/vggroup

Supporting information for this article is available on the WWW under http://dx.doi.org/10.1002/anie.200907291.

Scheme 2. Synthesis of imidazopyridines by a TCC approach.

reaction of 2-aminopyridine **1**, aldehyde **2,** and terminal alkyne **3**.[6] Notably, the 5-exo-dig cyclization of **4** to **5** should secure the formation of the imidazo[1,2-a]pyridylmethyl unit, a common fragment of the previously mentioned, biologically important molecules[2] (Scheme 1). To test this hypothesis, we examined the reaction in the presence of different metal catalysts. Accordingly, NaAuCl₄, known to be an efficient catalyst for the synthesis of indolizines through a TCC reaction,[7] was first tested. However, no desired product was formed under these reaction conditions (Table 1, entry 1). Further optimization revealed copper salts to be more efficient catalysts for this transformation. Thus, reactions in the presence of 5 mol% of Cu(OTf)₂ produced **5a** in 10%

Table 1: Optimization of the TCC reaction conditions.[a]

Entry	Catalyst (mol%)	Solvent	T [°C]	Yield of 5a [%][b]
1	NaAuCl₄·2H₂O (5)	toluene	120	0
2	Cu(OTf)₂ (5)	toluene	120	10
3	CuCl (10)	toluene	120	55
4	CuCl (50)	toluene	120	74
5	CuCl (5), Cu(OTf)₂ (5)	MeCN	100	15
6	CuCl (5), Cu(OTf)₂ (5)	DMA	120	78
7	**CuCl (5), Cu(OTf)₂ (5)**	**toluene**	**120**	**93**
8	CuCl (5), Cu(OTf)₂ (5)	toluene	120	76[c]

[a] Reaction conditions: 2-aminopyridine (0.1 mmol), benzaldehyde (0.105 mmol), acetylene (0.11 mmol), CuCl (0.005 mmol), Cu(OTf)₂ (0.005 mmol), solvent (1 M, 0.1 mL), 16 h. [b] Yields were determined by GC-MS analysis with pentadecane as an internal standard. [c] Reaction was performed in air. DMA = N,N-dimethylacetamide.

yield (Table 1, entry 2). Meanwhile, the use of 10 mol% of CuCl resulted in a dramatic improvement in the yield (55%; Table 1, entry 3). However, reactions in the presence of 50 mol% of CuCl produced **5a** in only 74% yield. (Table 1, entry 4). Employment of the CuCl/Cu-(OTf)$_2$[8] binary catalytic system[9] in MeCN at 100°C provided the desired product **5a** in 15% yield (78%; Table 1, entry 5). Surprisingly, the use of DMA at 120°C substantially improved the reaction outcome (78%; Table 1, entry 6). Finally, replacement of DMA with the less polar toluene afforded imidazopyridine **5a** from 2-aminopyridine **1a** (1 equiv), aldehyde **2a** (1.05 equiv), and alkyne **3a** (1.5 equiv) in excellent yield (93%; Table 1, entry 7). The reaction performed in air provided **5a** in lower yield (76%; Table 1, entry 8).

Next, the generality of this novel TCC reaction was examined (Table 2). To our delight, we found this transformation to be very general for a wide range of aldehydes and alkynes, and provided easy access to densely substituted imidazopyridine derivatives **5**. Thus, employment of different alkyne substrates, bearing aryl (Table 2, entries 1, 2, 6–10, and 12–22), alkyl (Table 2, entries 3–5), or silyl (Table 2, entry 11) substituents, produced imidazopyridines in good to exellent yields. Aryl and alkyl aldehydes also displayed good reactivity in this reaction. A variety of functional groups substituted at the aromatic ring of the aldehyde substrate, such as chloro (Table 2, entry 6), bromo (Table 2, entry 12), cyano (Table 2, entries 10, 13, and 18) and fluoro (Table 2, entries 14 and 15) groups were tolerated. The reaction with propyl and isopropyl aldehydes was uneventful, and furnished C2-alkyl-substituted imidazopyridines **5g** and **5h**, respectively (Table 2, entries 7 and 8). Employment of furan-2-carbaldehyde led to bishetaroaryl compound **5i** in 78% yield (Table 2, entry 9). Formaldehyde, however, was less reactive and provided monosubstituted imidazopyridine **5t** in moderate yield (Table 2, entry 20). Furthermore, 2-aminoquinoline and 2-aminoisoquinoline reacted well in this transformation, thus affording imidazoquinoline **5u** and imidazoisoquinoline **5v**, respectively, in good yields (Table 2, entries 21 and 22).

Table 2: Synthesis of imidazoheterocycles.[10]

Entry	Product		Yield [%][a]	Entry	Product		Yield [%][a]
1	**5a**	2-Ph, CH$_2$-Ph	92	12	**5l**	2-*p*-BrC$_6$H$_4$, CH$_2$-Ph	89
2	**5b**	2-Ph, CH$_2$-*p*-tolyl	90	13	**5m**	2-*p*-CNC$_6$H$_4$, CH$_2$-Ph	80
3	**5c**	2-Ph, CH$_2$OMe	79	14	**5n**	2-*p*-FC$_6$H$_4$, CH$_2$-Ph	90
4	**5d**	2-Ph, CH$_2$OTBS	70	15	**5o**	2-*p*-FC$_6$H$_4$, CH$_2$-*p*-tolyl	86
5	**5e**	2-Ph, *n*Bu	44[b]	16	**5p**	Me, 2-Ph, CH$_2$-Ph	50[c]
6	**5f**	2-*m*-ClC$_6$H$_4$, CH$_2$-Ph	81	17	**5q**	Me, 2-Ph, CH$_2$-Ph	61
7	**5g**	2-*n*Pr, CH$_2$-Ph	56[b]	18	**5r**	Me, 2-*p*-CNC$_6$H$_4$, CH$_2$-*p*-tolyl	87
8	**5h**	2-*i*Pr, CH$_2$-Ph	60	19	**5s**	Me, 2-*p*-tolyl, CH$_2$-*p*-tolyl	83
9	**5i**	2-furyl, CH$_2$-Ph	78	20	**5t**	2-H, CH$_2$-Ph	50[c]
10	**5j**	2-*p*-CNC$_6$H$_4$, CH$_2$-*p*-tolyl	82	21	**5u**	2-Ph, CH$_2$-Ph	70
11	**5k**	2-Ph, CH$_2$-TIPS	73	22	**5v**	2-Ph, CH$_2$-Ph	65

[a] Yield of isolated product. [b] Product decomposes upon prolonged heating. [c] Some 2-amino-pyridine and benzaldehyde did not react. [d] Corresponding imine was isolated in 48% yield. TBS = *tert*-butyldimethylsilyl, TIPS = triisopropylsilyl.

Next, we attempted the synthesis of alpidem (**A**) and zolpidem (**B**) through this novel three-component coupling reaction. It should be mentioned that these drugs are usually synthesized by multistep procedures.[11] We hypothesized that **A** and **B** could rapidly be accessed through a three-component coupling reaction of the appropriate aminopyridine, aldehyde, and corresponding propiolamide. We recognized that employment of propiolamide as a starting material would be challenging, as this Michael acceptor would not be tolerated in the first step of the sequence. Thus, we performed model studies of the TCC reaction with propiolates (Scheme 3). It was found that imidazopyridines **6a–c** could be synthesized in good yields in a one-pot fashion, where ethyl

Scheme 3. Model studies of the one-pot TCC reaction. M.S. = molecular sieves (4 Å).

propyolate and copper catalysts were added to the reaction mixture upon completion of the dehydrocondensation step.

By using the newly established protocol, the one-pot syntheses of zolpidem and alpidem were carried out by employing the corresponding propiolamides (Scheme 4). Gratifyingly, the sequential TCC reaction of 2-amino-5-

Scheme 4. One-pot synthesis of alpidem and zolpidem.

chloropyridine (**1b**) and *p*-chloroaldehyde (**2b**) with *N,N*-dipropylpropiolamide produced alpidem (**A**) in 83% yield. Likewise, the reaction of 2-amino-5-methylpyridine (**1c**), and *p*-tolualdehyde (**2c**) with *N,N*-dimethylpropiolamide afforded zolpidem (**B**) in 72% yield.

In conclusion, we have developed a general and highly efficient method for the synthesis of imidazopyridine derivatives by the copper-catalyzed three-component coupling reaction of aryl, heteroaryl, and alkyl aldehydes with 2-aminopyridines and terminal alkynes. The employment of 2-aminoquinoline and 2-aminoisoquinoline as coupling partners in this transformation led to imidazoquinoline and imidazoisoquinoline frameworks in good yields. The synthetic utility of this novel TCC reaction has been illustrated in a highly efficient one-pot synthesis of alpidem and zolpidem.

Experimental Section

Typical procedure for the synthesis of imidazopyridines **5a–v**: 2-Aminopyridine **1** (0.5 mmol), CuCl (2.5 mg, 0.025 mmol, 5 mol%), Cu(OTf)$_2$ (9.04 mg, 0.025 mmol, 5 mol%), and aldehyde **2** (only added at this point if solid) was added to a Weaton (1 mL) microreactor in a glovebox under an inert atmosphere. Subsequently, anhydrous toluene (500 µL, 1M), aldehyde **2** (0.525 mmol, 1.05 equiv), and alkyne **3** (0.75 mmol, 1.5 equiv) were added to the mixture. The microreactor was capped with a Teflon pressure cap and placed into a preheated (120 °C) aluminum heating block. The reaction mixture was heated at 120 °C until full consumption of 2-aminopyridine **1** (as evident by GC-MS analysis). Upon completion (12–16 h) of the reaction the mixture was filtered through a plug of neutral alumina (eluent: EtOAc). The filtrate was concentrated under reduced pressure to give the crude material, which was purified by column chromatography on silica gel (eluent: Et$_3$N/EtOAc/hexanes 4:17:84), and afforded imidazopyridine **5**.

[1] For a general review on the chemistry of imidazopyridine derivatives, see: F. Couty, G. Evano in *Comprehensive Heterocyclic Chemistry III*, *Vol. 11* (Eds.: A. R. Katritzky, C. A. Ramsden, E. F. V. Scriven, R. J. K. Taylor), Elsevier, Oxford, **2008**, pp. 409–499, and references therein.

[2] For selected examples of biologically active imidazo[1,2-*a*]pyridyl derivatives, see: a) T. Okubo, R. Yoshikawa, S. Chaki, S. Okuyamac, A. Nakazato, *Bioorg. Med. Chem.* **2004**, *12*, 423; b) A. N. Jain, *J. Med. Chem.* **2004**, *47*, 947; c) T. Swainston Harrison, G. M. Keating, *CNS Drugs* **2005**, *19*, 65; d) N. Hsua, S. K. Jha, T. Coleman, M. G. Frank, *Behav. Brain Res.* **2009**, *201*, 233; e) M. H. Wiegand, *Drugs* **2008**, *68*, 2411; f) S. M. Hanson, E. V. Morlock, K. A. Satyshur, C. Czajkowski, *J. Med. Chem.* **2008**, *51*, 7243; g) J. B. Véron, H. Allouchi, C. Enguehard Gueiffier, R. Snoeck, G. A. E. De Clercq, A. Gueiffier, *Bioorg. Med. Chem.* **2008**, *16*, 9536.

[3] For selected examples on the synthesis of imidazo[1,2-*a*]pyridine derivatives, see: a) C. J. R. Fookes, T. Q. Pham, F. Mattner, I. Greguric, C. Loc'h, X. Liu, P. Berghofer, R. Shepherd, M. C. Gregoire, A. Katsifis, *J. Med. Chem.* **2008**, *51*, 3700; b) N. Denora, V. Laquintana, M. G. Pisu, R. Dore, L. Murru, A. Latrofa, G. Trapani, E. Sanna, *J. Med. Chem.* **2008**, *51*, 6876; c) V. Laquintana, N. Denora, A. Lopedota, H. Suzuki, M. Sawada, M. Serra, G. Biggio, A. Latrofa, G. Trapani, G. Liso, *Bioconjugate Chem.* **2007**, *18*, 1397; d) G. Trapani, V. Laquintana, N. Denora, A. Trapani, A. Lopedota, A. Latrofa, M. Franco, M. Serra, M. G. Pisu, I. Floris, E. Sanna, G. Biggio, G. Liso, *J. Med. Chem.* **2005**, *48*, 292.

[4] For multicomponent approaches limited to the synthesis of 3-aminoimidazo[1,2-*a*]pyridine derivatives, see: a) A. L. Rousseau, P. Matlaba, C. J. Parkinson, *Tetrahedron Lett.* **2007**, *48*, 4079; b) E. F. DiMauro, J. M. Kennedy, *J. Org. Chem.* **2007**, *72*, 1013; c) M. A. Lyon, T. S. Kercher, *Org. Lett.* **2004**, *6*, 4989; d) T. Masquelin, H. Bui, B. Brickley, G. Stephenson, J. Schwerkosked, C. Hulmea, *Tetrahedron Lett.* **2006**, *47*, 2989.

[5] For examples on the synthesis of fused heterocycles by copper and palladium-catalyzed 5-*exo-dig* heteroannulations, see: a) R. Martín, M. Rodríguez Rivero, S. L. Buchwald, *Angew. Chem.* **2006**, *118*, 7237; *Angew. Chem. Int. Ed.* **2006**, *45*, 7079; b) M. Bakherad, H. Nasr-Isfahani, A. Keivanloo, G. Sang, *Tetrahedron Lett.* **2008**, *49*, 6188; c) M. Bakherad, H. Nasr-Isfahani, A.

Keivanloo, N. Doostmohammadi, *Tetrahedron Lett.* **2008**, *49*, 3819.

[6] For selected examples of copper-catalyzed syntheses of propargylamine derivatives by a TCC reaction, see: a) M. K. Patil, M. Keller, B. M. Reddy, P. Pale, J. Sommer, *Eur. J. Org. Chem.* **2008**, 4440; b) M. Lakshmi Kantam, S. Laha, J. Yadav, S. Bhargava, *Tetrahedron Lett.* **2008**, *49*, 3083; for gold-catalyzed, see: c) V. K. Y. Loa, K. K. Y. Kung, M. K. Wong, C. M. Che, *J. Organomet. Chem.* **2009**, *694*, 583; d) X. Zhang, A. Corma, *Angew. Chem.* **2008**, *120*, 4430; *Angew. Chem. Int. Ed.* **2008**, *47*, 4358; e) M. Kidwai, V. Bansal, A. Kumarb, S. Mozumdar, *Green Chem.* **2007**, *9*, 742; for other transition-metal-catalyzed reactions, see: f) Y. Zhang, P. Li, M. Wang, L. Wang, *J. Org. Chem.* **2009**, *74*, 4364; g) P. Li, Y. Zhang, L. Wang, *Chem. Eur. J.* **2009**, *15*, 2045; for the enantioselective version, see: h) C. J. Li, C. Wei, *Chem. Commun.* **2002**, 268; i) N. Gommermann, C. Koradin, K. Polborn, P. Knochel, *Angew. Chem.* **2003**, *115*, 5941; *Angew. Chem. Int. Ed.* **2003**, *42*, 5763; j) T. F. Knöpfel, P. Aschwanden, T. Ichikawa, T. Watanabe, E. M. Carreira, *Angew. Chem.* **2004**, *116*, 6097; *Angew. Chem. Int. Ed.* **2004**, *43*, 5971; k) A. Bisai, V. K. Singh, *Org. Lett.* **2006**, *8*, 2405.

[7] B. Yan, Y. Liu, *Org. Lett.* **2007**, *9*, 4323.

[8] Apparently, CuCl is a better catalyst for the synthesis of propargylamine **4** by the three-component coupling reaction of the corresponding 2-aminopyridine, aldehyde, and acetylene, whereas Cu(OTf)$_2$ is more efficient for the subsequent 5-*exo-dig* cyclization of **4** to give the imidazo[1,2-a]pyridyl core **5**. See Ref. [9] and the discussion therein.

[9] For use of the Cu^I/Cu^{II} binary system in the synthesis of benzofuran derivatives, see: N. Sakai, N. Uchida, T. Konakahara, *Tetrahedron Lett.* **2008**, *49*, 3437.

[10] See the Supporting Information for details.

[11] a) Y. Sumalatha, T. R. Reddy, P. P. Reddy, B. Satyanarayana, *ARKIVOC* **2008**, *2*, 315; b) J. Allen, G. Parent, A. Tizot, *J. Labelled Compd. Radiopharm.* **1986**, *23*, 807; c) J. Allen, A. Tizot, *J. Labelled Compd. Radiopharm.* **1986**, *23*, 393; for patents, see the Supporting Information.